Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.
CITATION STYLE
Sasaki, T., Kawashima, H., Ariizumi, T., Yamagishi, T., Oike, N., Umezu, H., … Ogose, A. (2017). Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast‑like giant cells: A case report. Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2017.1489
Mendeley helps you to discover research relevant for your work.